Newsfeeds Archive - Spark Newswire

1 minute read

News

Innate Pharma And Sanofi’s Blood Cancer Treatment SAR443579/IPH6101 Shows Over 10 Months Of Durable Complete Remission In Phase 1/2 Study, Results Discussed At EHA Congress

June 17, 2:20 AM

SAR443579/IPH6101, ANKET® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by

IPHA

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights

April 3, 4:31 PM

Gainers Aesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday’s after-market session. The company’s market cap…

ACOR

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s Pre-Market Session

By Benzinga Insights

April 1, 8:08 AM

Gainers Galera Therapeutics (NASDAQ:GRTX) shares moved upwards by 62.8% to $0.23 during Monday’s pre-market session. The market value…

APLT

1 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

February 6, 9:06 AM

Gainers Exicure (NASDAQ:XCUR) shares rose 55.5% to $0.87 during Tuesday’s pre-market session. The market value of their outstanding…

ADAP

1 minute read

News

Reported On Sunday, Innate Pharma To Present Results From TELLOMAK Phase 2 Study With Lacutamab In Patients With Sézary Syndrome At ASH 2023

By Benzinga Newsdesk

December 11, 4:21 AM

Results confirm promising clinical activity, durable responses and favorable safety of lacutamab in heavily pretreated post-mogamulizumab Sézary Syndrome patients. As of May 1, 2023, data cutoff, patients in

IPHA

1 minute read

Movers

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

October 5, 9:10 AM

Gainers Dyadic International (NASDAQ:DYAI) shares rose 10.9% to $2.24 during Thursday’s pre-market session. The company’s market cap stands…

CMRA

1 minute read

Regulatory Hurdle For Innate Pharma’s Blood Cancer Studies

By Vandana Singh

October 5, 8:19 AM

The FDA has placed a clinical hold on Innate Pharma SA's (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL).

IPHA

1 minute read

Innate Pharma Establishes A New At-The-Market Program On Nasdaq; Company May Offer And Sell A Total $75M Co. ADS From Time To Time

By Happy Mohamed

April 27, 7:10 AM

Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that it has filed a prospectus supplement with the Securities and Exchange Commission ("SEC") relating

IPHA

1 minute read